View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 30, 2020updated 12 Jul 2022 11:40am

Sanofi begins dosing of DNL758 in Phase Ib Covid-19 trial

Denali Therapeutics has announced that its partner Sanofi has started dosing of a small molecule RIPK1 inhibitor, DNL758, in a Phase Ib clinical trial involving hospitalised adults with severe Covid-19 lung disease.

Denali Therapeutics has announced that its partner Sanofi has started dosing of a small molecule RIPK1 inhibitor, DNL758, in a Phase Ib clinical trial involving hospitalised adults with severe Covid-19 lung disease.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

RIPK1, a receptor-interacting serine/threonine-protein kinase 1, serves as a signaling protein in the TNF receptor pathway, which modulates inflammation and cell death in body tissues.

In severe Covid-19 patients, a RIPK1 inhibitor is expected to reduce the exaggerated immune response to SARS-CoV-2 and limit any tissue damage caused by excessive inflammation.

The randomised, double-blind, placebo-controlled Phase Ib study is designed to assess DNL758’s safety and impact on the immune system in severe Covid-19 cases.

The study will be completed in January next year and is expected to enrol around 67 participants.

Denali Therapeutics CEO Ryan Watts said: “We know that inhibition of RIPK1, a known target in the TNF-pathway, can significantly modulate the body’s immune response.

“Our partner Sanofi is expanding its clinical investigation of DNL758 into patients with severe Covid-19. We are proud to stand with Sanofi in this effort, with the aim to contribute solutions in the fight against this terrible pandemic.”

Denali and Sanofi collaborated in October 2018 for the global development and commercialisation of RIPK1 inhibitors.

Apart from Covid-19, the company are evaluating DNL788 in CNS indications and DNL758 in peripheral inflammatory indications.

Sanofi agreed to develop and commercialise DNL758, as well as cover all costs related to the drug candidate, while Denali is eligible for development and sales milestones and sales royalties.

Earlier this month, Sanofi and Regeneron Pharmaceuticals reported that a Phase III trial of rheumatoid arthritis drug Kevzara failed to meet its primary and key secondary endpoints in Covid-19 patients who required mechanical ventilation in the US.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena